The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Open accessAbstract
Introduction: 177Lutetium-[DOTA°,Tyr3]octreotate (177Lu-DOTATATE) is a type of peptide receptor radionuclide therapy that garnered FDA approval in January 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients. The therapy approval was based on findings from the randomized international phase III NETTER-1 trial as well as outcome data from a large European registry. The mechanism of the drug stems directly from its structure: a somatostatin analog (octreotate) selectively binding to somatostatin receptor expressing cells and being internalized, along with a chelated beta-emitting isotope 177Lu.Areas Covered: Herein we describe the pharmacology, clinical efficacy and adverse event data from prospective and retrospective studies with 177Lu-DOTATATE. We discuss the role of 177Lu-DOTATATE within the current treatment landscape for GEP NET patients.Expert Opinion: 177Lu-DOTATATE represents a unique addition to the treatment armamentarium for GEP NETs because of its potential to elicit tumor cytoreduction, which is rare among other existing treatment options, and prolonged disease control. Where 177Lu-DOTATATE fits into the treatment sequence for GEP NET patients remains an area of active investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“An excellent example is 177Lu-DOTATATE, a radiolabelled somatostatin analogue, used to treat neuroendocrine tumors (NETs) [91].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasari, A. N., Shen, C., Halperin, D. M., Zhao, B., Zhou, S., Xu, Y., Shih, Y. T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,457 · cited 2×
“Article highlights ● 177Lu-DOTATATE is a radiolabeled somatostatin agonist (SSA), which is approved for the treatment of somatostatin receptor positive welldifferentiated gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients in Europe, the United States, and Canada.”
BackgroundPhase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308 · cited 1×
“The NETTER-1 study was a randomized phase III trial in patients with progressive metastatic or unresectable well-differentiated midgut neuroendocrine tumors [34].”
BackgroundSelf-citationEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, É., Dahan, L., Raoul, J., Bang, Y., Borbath, I., Lombard‐Bohas, C., Valle, J. W., Metrakos, P. P., Smith, D. M., Vinik, A. I., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567 · cited 1×
“proven cytostatic activity for pancreatic NETs only [8].”
BackgroundRinke, A., Müller, H., Schade‐Brittinger, C., Klose, K., Barth, P. J., Wied, M., Mayer, C., Aminossadati, B., Pape, U., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,507 · cited 1×
“or those with hormonal over-production leading to syndromes, long-acting somatostatin agonists (SSAs) have been the cornerstone of first-line therapy [4,5].”
BackgroundLanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M. E., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,937 · cited 1×
“or those with hormonal over-production leading to syndromes, long-acting somatostatin agonists (SSAs) have been the cornerstone of first-line therapy [4,5].”
Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E. M., Tomášek, J., Raderer, M., Lahner, H., Voi, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00817-x · Cited by 1,290
Self-citationNothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B. T., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 766 · cited 1×
“Gastroenteropancreatic (GEP) NETs represent the most common subtype of well-differentiated NETs, comprising more than 70% of these neoplasms [2].”
BackgroundStrosberg, J., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J. F., & Kvols, L. K. (2010) · Cancer · doi:10.1002/cncr.25425 · Cited by 763
Self-citationImhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H. F., Mäcke, H. R., Rochlitz, C. F., Müller‐Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641 · cited 1×
“2% experienced permanent nephrotoxicity (grade ≥ 4) [29].”
Research works printed but not linked: 4
- Barone R, 2005, J Nucl Med, 46, 99S
- Strosberg J, 2018, J Clin Oncol, 36(25):2578–258
- Zhang J, 2019, J Nucl Med, 60, 560
- Forrer F, 2005, J Nucl Med, 46, 1310
Cited by
Sorted by citations
Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00572-6 · Cited by 605
Self-citationDelpassand, E. S., Tworowska, I., Esfandiari, R., Torgue, J., Hurt, J., Shafie, A., & Núñez, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263230 · Cited by 199
“Food and Drug Administration for patients with SSTR-expressing gastroenteropancreatic NETs (5).”
BackgroundTargeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.
Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194
“Clinical success has been demonstrated with the β− emitters 90Y and 131I conjugated with anti-CD20 monoclonal antibodies in follicular B-cell non-Hodgkin lymphoma [6], 177Lu-labeled prostate-specific membrane antigen (PSMA) peptides in metastatic, castrationresistant prostate cancer (CRPC) and 177Lu-DOTATATE for neuro…”
BackgroundPeptide–drug conjugate-based novel molecular drug delivery system in cancer
Zhu, Y., Tang, K., & Lv, J. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.07.001 · Cited by 157
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
“An excellent example is 177 Lu-DOTATATE, a radiolabelled somatostatin analogue, used to treat neuroendocrine tumors (NETs) [91].”
Background
Metadata
- Authors
- Das, S., Al-Toubah, T., El-Haddad, G., & Strosberg, J.
- Affiliations
- Vanderbilt University Medical Center (US)
- Department of GI Oncology, Moffitt Cancer Center, Tampa, FL, USA
- Moffitt Cancer Center (US)
- Corresponding author
- Das, Satya
- Venue
- Expert Review of Gastroenterology & Hepatology
- Publisher
- Informa UK Limited
- Published
- 2019-10-30
- Volume
- 13
- Issue
- 11
- Pages
- 1023-1031
- ISSN
- 1747-4124 (ISSN-L)
- 1747-4132
- PMC
- PMC7227421
- OpenAlex
- W2981499856
- Cited by
- 135
- References
- 53
- Citations by year
- 2026: 23 · 2025: 32 · 2024: 32 · 2023: 15 · 2022: 20 · 2021: 9 · 2020: 4
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Review of Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K12CA090625)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- 177Lu-DOTATATE, peptide receptor radionuclide therapy, gastroenteropancreatic neuroendocrine tumors, somatostatin receptors, octreotate, NETTER-1 trial, treatment efficacy, adverse events, treatment sequencing
- MeSH terms
- Animals, Gastrointestinal Neoplasms, Humans, Organometallic Compounds, Pancreatic Neoplasms, Octreotide, Treatment Outcome, Neuroendocrine Tumors, Radiopharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
